Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib

Akihiro Yamasaki, Narihiro Umeno, Shigeru Harada, Kosuke Tanaka, Masaki Kato, Kazuhiro Kotoh

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

We encountered two patients with hepatocellular carcinoma (HCC) who showed rapid progression of liver failure during sorafenib treatment. One had portal vein tumor thrombus (PVTT) and the other developed portal vein thrombosis (PVT) during the treatment, and both of them experienced the elevation of serum lactate dehydrogenase (LDH) concentration during the administration of sorafenib. Their clinical courses indicate that the liver failure might have been caused by sorafenib-induced liver hypoxia, being amplified in the circumstances with reduced portal flow. To our best knowledge, all the reported patients who achieved complete remission (CR) during sorafenib monotherapy had a condition that could decrease portal blood flow. We hypothesized that pathogenesis of disease may be similar in HCC patients who achieve CR and those who experience liver failure while on sorafenib. Sorafenib treatment of patients with HCC and deteriorated portal flow may be a double-edged sword.

元の言語英語
ページ(範囲)E36-E40
ジャーナルJournal of Gastrointestinal Oncology
7
発行部数3
DOI
出版物ステータス出版済み - 6 1 2016

Fingerprint

Liver Failure
Hepatocellular Carcinoma
Portal Vein
Thrombosis
L-Lactate Dehydrogenase
sorafenib
Therapeutics
Liver
Serum
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

これを引用

Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib. / Yamasaki, Akihiro; Umeno, Narihiro; Harada, Shigeru; Tanaka, Kosuke; Kato, Masaki; Kotoh, Kazuhiro.

:: Journal of Gastrointestinal Oncology, 巻 7, 番号 3, 01.06.2016, p. E36-E40.

研究成果: ジャーナルへの寄稿記事

Yamasaki, Akihiro ; Umeno, Narihiro ; Harada, Shigeru ; Tanaka, Kosuke ; Kato, Masaki ; Kotoh, Kazuhiro. / Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib. :: Journal of Gastrointestinal Oncology. 2016 ; 巻 7, 番号 3. pp. E36-E40.
@article{eaad57a89c5248a59756c4d461836f48,
title = "Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib",
abstract = "We encountered two patients with hepatocellular carcinoma (HCC) who showed rapid progression of liver failure during sorafenib treatment. One had portal vein tumor thrombus (PVTT) and the other developed portal vein thrombosis (PVT) during the treatment, and both of them experienced the elevation of serum lactate dehydrogenase (LDH) concentration during the administration of sorafenib. Their clinical courses indicate that the liver failure might have been caused by sorafenib-induced liver hypoxia, being amplified in the circumstances with reduced portal flow. To our best knowledge, all the reported patients who achieved complete remission (CR) during sorafenib monotherapy had a condition that could decrease portal blood flow. We hypothesized that pathogenesis of disease may be similar in HCC patients who achieve CR and those who experience liver failure while on sorafenib. Sorafenib treatment of patients with HCC and deteriorated portal flow may be a double-edged sword.",
author = "Akihiro Yamasaki and Narihiro Umeno and Shigeru Harada and Kosuke Tanaka and Masaki Kato and Kazuhiro Kotoh",
year = "2016",
month = "6",
day = "1",
doi = "10.21037/jgo.2015.10.07",
language = "English",
volume = "7",
pages = "E36--E40",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "3",

}

TY - JOUR

T1 - Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib

AU - Yamasaki, Akihiro

AU - Umeno, Narihiro

AU - Harada, Shigeru

AU - Tanaka, Kosuke

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

PY - 2016/6/1

Y1 - 2016/6/1

N2 - We encountered two patients with hepatocellular carcinoma (HCC) who showed rapid progression of liver failure during sorafenib treatment. One had portal vein tumor thrombus (PVTT) and the other developed portal vein thrombosis (PVT) during the treatment, and both of them experienced the elevation of serum lactate dehydrogenase (LDH) concentration during the administration of sorafenib. Their clinical courses indicate that the liver failure might have been caused by sorafenib-induced liver hypoxia, being amplified in the circumstances with reduced portal flow. To our best knowledge, all the reported patients who achieved complete remission (CR) during sorafenib monotherapy had a condition that could decrease portal blood flow. We hypothesized that pathogenesis of disease may be similar in HCC patients who achieve CR and those who experience liver failure while on sorafenib. Sorafenib treatment of patients with HCC and deteriorated portal flow may be a double-edged sword.

AB - We encountered two patients with hepatocellular carcinoma (HCC) who showed rapid progression of liver failure during sorafenib treatment. One had portal vein tumor thrombus (PVTT) and the other developed portal vein thrombosis (PVT) during the treatment, and both of them experienced the elevation of serum lactate dehydrogenase (LDH) concentration during the administration of sorafenib. Their clinical courses indicate that the liver failure might have been caused by sorafenib-induced liver hypoxia, being amplified in the circumstances with reduced portal flow. To our best knowledge, all the reported patients who achieved complete remission (CR) during sorafenib monotherapy had a condition that could decrease portal blood flow. We hypothesized that pathogenesis of disease may be similar in HCC patients who achieve CR and those who experience liver failure while on sorafenib. Sorafenib treatment of patients with HCC and deteriorated portal flow may be a double-edged sword.

UR - http://www.scopus.com/inward/record.url?scp=84995758324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995758324&partnerID=8YFLogxK

U2 - 10.21037/jgo.2015.10.07

DO - 10.21037/jgo.2015.10.07

M3 - Article

VL - 7

SP - E36-E40

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 3

ER -